Last reviewed · How we verify
Low Bup Dose
Low-dose buprenorphine acts as a partial agonist at the mu-opioid receptor, providing analgesia and potentially reducing opioid cravings with lower overdose risk than full opioids.
Low-dose buprenorphine acts as a partial agonist at the mu-opioid receptor, providing analgesia and potentially reducing opioid cravings with lower overdose risk than full opioids. Used for Opioid use disorder, Chronic pain management.
At a glance
| Generic name | Low Bup Dose |
|---|---|
| Also known as | Subutex |
| Sponsor | New York State Psychiatric Institute |
| Drug class | Partial mu-opioid receptor agonist |
| Target | Mu-opioid receptor (OPRM1) |
| Modality | Small molecule |
| Therapeutic area | Pain Management / Psychiatry / Substance Use Disorder |
| Phase | Phase 3 |
Mechanism of action
Buprenorphine is a semi-synthetic opioid that binds with high affinity but partial agonist activity at mu-opioid receptors. At low doses, it produces analgesic and anti-craving effects while maintaining a ceiling effect on respiratory depression, making it safer than full opioid agonists. This profile makes it suitable for pain management and opioid use disorder treatment with reduced overdose potential.
Approved indications
- Opioid use disorder
- Chronic pain management
Common side effects
- Constipation
- Nausea
- Headache
- Dizziness
- Sweating
Key clinical trials
- Extended-release Buprenorphine as a Novel Low-dose Induction Strategy (PHASE2)
- Low-dose Buprenorphine Initiation for Opioid Use Disorder (PHASE4)
- Abuse Liability of Suboxone Versus Subutex (PHASE3)
- Low Dose Naltrexone-buprenorphine Transfer to Vivitrol Injection in Opioid Dependence (PHASE2)
- Rapid Opiate Detoxification and Naltrexone Induction Using Buprenorphine - 2 (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |